Showing 1 - 10 of 17
Background:Background: In 2005, the French Government implemented a new way of financing high-cost drugs for hospitals in order to promote innovation. Such drugs are gathered on a positive list, established by the Ministry of Health, with a reimbursement price cap. Hospitals still negotiate with...
Persistent link: https://www.econbiz.de/10011005079
Persistent link: https://www.econbiz.de/10009493380
Previous application of value-of-information methods to optimal clinical trial design have predominantly taken a societal decision-making perspective, implicitly assuming that healthcare costs are covered through public expenditure and trial research is funded by government or donation-based...
Persistent link: https://www.econbiz.de/10010548289
Persistent link: https://www.econbiz.de/10010614333
Persistent link: https://www.econbiz.de/10010614367
Background: Market authorization does not guarantee patient access to any given drug. This is particularly true for costly orphan drugs because access depends primarily on co-payments, reimbursement policies and prices. The objective of this article is to identify differences in the availability...
Persistent link: https://www.econbiz.de/10010614375
introduction of reference pricing (RP) policies in Organisation for Economic Co-operation and Development (OECD) countries. We …
Persistent link: https://www.econbiz.de/10010614402
EU countries closely regulate pharmaceutical prices, whereas the US does not. This paper shows how price constraints affect the profitability, stock returns and R&D spending of EU and US firms. Compared with EU firms, US firms are more profitable, earn higher stock returns and spend more on R&D....
Persistent link: https://www.econbiz.de/10008465562
cap) and by setting the maximum reimbursement rate, especially by means of reference pricing systems. We analyse current … reimbursement rate, particularly through reference pricing and similar tools, on dynamic price competition between generic …/or regulation of the reimbursement rate (reference pricing or similar systems) on price dynamics, corresponding to pharmacy sales …
Persistent link: https://www.econbiz.de/10008465564
were unavailable. Superior mechanisms lie somewhere between a first best pricing solution for the entire economy at one … intertemporal bounty is the best way to meet the multiple objectives of immediate distribution at marginal cost pricing of newly …
Persistent link: https://www.econbiz.de/10005590430